Amgen Inc. logo
Amgen Inc. (AMGN)
Compare

Amgen Inc. (AMGN) Earnings Yield: 4.26%

Is Amgen Inc.’s earnings yield high or low?

Amgen Inc.'s earnings yield of 4.26% is in line with its 5-year average of 4.18%, around the middle of its 5-year range (1.72%–6.86%).

As of Thursday, June 11, 2026. 6.33% above its 12-month average of 4.01%.

AMGN Earnings Yield Chart

AMGN Earnings Yield
4.26%+13.90% 1Y
Zoom

AMGN Average Earnings Yield Chart

AMGN Current vs Average Earnings Yield Chart

AMGN Earnings Yield Metrics

EARNINGS YIELD

4.26%

EARNINGS YIELD AVG TTM

4.01%

EARNINGS YIELD AVG 3Y

3.83%

EARNINGS YIELD AVG 5Y

4.18%

EARNINGS YIELD AVG 10Y

4.65%

EARNINGS YIELD AVG 15Y

5.00%

EARNINGS YIELD AVG 20Y

5.37%

CURRENT VS TTM AVG

+6.33%

CURRENT VS 3Y AVG

+11.26%

CURRENT VS 5Y AVG

+1.86%

CURRENT VS 10Y AVG

-8.45%

CURRENT VS 15Y AVG

-14.85%

CURRENT VS 20Y AVG

-20.73%

AMGN Competitors' Earnings Yield

NAMEMARKET CAPEARNINGS YIELDTTM3Y5Y
Amgen Inc. (AMGN)$188.37B4.26%4.01%3.83%4.18%
Thermo Fisher Scientific Inc. (TMO)$176.21B3.83%3.47%3.14%3.26%
Gilead Sciences, Inc. (GILD)$156.35B6.04%4.73%3.68%4.37%
Abbott Laboratories (ABT)$155.75B4.01%5.49%4.05%3.87%
Pfizer Inc. (PFE)$149.61B4.99%6.28%6.38%7.46%
Intuitive Surgical, Inc. (ISRG)$144.79B2.00%1.54%1.36%1.43%
Danaher Corporation (DHR)$127.91B2.82%2.43%2.72%3.03%
CVS Health Corporation (CVS)$126.81B2.32%2.92%5.90%5.70%
Bristol-Myers Squibb Company (BMY)$116.13B6.26%5.70%6.24%5.43%
Vertex Pharmaceuticals Incorporated (VRTX)$110.59B3.83%3.41%3.43%3.73%

Earnings Yield vs P/E Ratio

Earnings Yield

4.26%

EPS ÷ Price

P/E Ratio

23.5

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

  • It expresses earnings relative to share price as a percentage
  • It can be compared with FCF yield and dividend yield
  • It can be compared with bond yields because both are percentages
  • It is mathematically the inverse of the P/E ratio

Amgen Inc. Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Amgen Inc. Earnings Yield FAQ

What is the earnings yield for Amgen Inc. (AMGN)?
The earnings yield for AMGN stock is 4.26%.
Is Amgen Inc.'s earnings yield high or low?
Amgen Inc.'s earnings yield of 4.26% is in line with its 5-year average of 4.18%, around the middle of its 5-year range (1.72%–6.86%).
What is the TTM average earnings yield for Amgen Inc. (AMGN)?
The TTM average earnings yield for AMGN stock is 4.01%.
What is the 3Y average earnings yield for Amgen Inc. (AMGN)?
The 3Y average earnings yield for AMGN stock is 3.83%.
What is the 5Y average earnings yield for Amgen Inc. (AMGN)?
The 5Y average earnings yield for AMGN stock is 4.18%.
What is the 10Y average earnings yield for Amgen Inc. (AMGN)?
The 10Y average earnings yield for AMGN stock is 4.65%.
What is the 15Y average earnings yield for Amgen Inc. (AMGN)?
The 15Y average earnings yield for AMGN stock is 5.00%.
What is the 20Y average earnings yield for Amgen Inc. (AMGN)?
The 20Y average earnings yield for AMGN stock is 5.37%.

Amgen Inc. Earnings Yield History

DATEEARNINGS YIELD
2026-06-104.26%
2026-06-094.17%
2026-06-084.16%
2026-06-054.11%
2026-06-044.16%
2026-06-034.25%
2026-06-024.38%
2026-06-014.37%
2026-05-294.27%
2026-05-284.27%
2026-05-274.28%
2026-05-264.28%
2026-05-224.24%
2026-05-214.26%
2026-05-204.33%
2026-05-194.34%
2026-05-184.43%
2026-05-154.40%
2026-05-144.27%
2026-05-134.27%
2026-05-124.27%
2026-05-114.36%
2026-05-084.33%
2026-05-074.37%
2026-05-064.34%
2026-05-054.36%
2026-05-044.44%
2026-05-014.36%
2026-04-304.15%
2026-04-294.21%
2026-04-284.19%
2026-04-274.18%
2026-04-244.13%
2026-04-234.08%
2026-04-224.11%
2026-04-214.13%
2026-04-204.06%
2026-04-174.00%
2026-04-164.07%
2026-04-154.09%
2026-04-144.06%
2026-04-134.07%
2026-04-104.05%
2026-04-094.00%
2026-04-084.07%
2026-04-074.19%
2026-04-064.15%
2026-04-024.09%
2026-04-014.03%
2026-03-314.04%
2026-03-304.08%
2026-03-274.08%
2026-03-264.03%
2026-03-254.02%
2026-03-244.08%
2026-03-234.07%
2026-03-204.09%
2026-03-194.07%
2026-03-184.05%
2026-03-173.94%
2026-03-163.89%
2026-03-133.89%
2026-03-123.87%
2026-03-113.77%
2026-03-103.79%
2026-03-093.78%
2026-03-063.85%
2026-03-053.87%
2026-03-043.75%
2026-03-033.78%
2026-03-023.69%
2026-02-273.67%
2026-02-263.75%
2026-02-253.70%
2026-02-243.72%
2026-02-233.75%
2026-02-203.80%
2026-02-193.79%
2026-02-183.75%
2026-02-173.81%
2026-02-133.86%
2026-02-123.53%
2026-02-113.53%
2026-02-103.55%
2026-02-093.44%
2026-02-063.37%
2026-02-053.52%
2026-02-043.53%
2026-02-033.82%
2026-02-023.75%
2026-01-303.79%
2026-01-293.77%
2026-01-283.78%
2026-01-273.68%
2026-01-263.70%
2026-01-233.75%
2026-01-223.73%
2026-01-213.77%
2026-01-203.91%
2026-01-163.92%
2026-01-153.92%
2026-01-143.93%
2026-01-133.99%
2026-01-123.97%
2026-01-093.97%
2026-01-083.92%
2026-01-073.79%
2026-01-063.92%
2026-01-054.03%
2026-01-023.95%
2025-12-313.95%
2025-12-303.94%
2025-12-293.93%
2025-12-263.89%
2025-12-243.87%
2025-12-233.90%
2025-12-223.90%
2025-12-193.95%
2025-12-183.99%
2025-12-173.97%
2025-12-163.96%
2025-12-153.98%
2025-12-124.07%
2025-12-114.08%
2025-12-104.10%
2025-12-094.12%
2025-12-084.03%
2025-12-053.92%
2025-12-043.80%
2025-12-033.75%
2025-12-023.82%
2025-12-013.83%
2025-11-283.75%
2025-11-263.76%
2025-11-253.79%
2025-11-243.87%
2025-11-213.83%
2025-11-203.85%
2025-11-193.78%
2025-11-183.76%
2025-11-173.79%
2025-11-143.84%
2025-11-133.85%
2025-11-123.85%
2025-11-113.82%
2025-11-104.00%
2025-11-074.04%
2025-11-064.10%
2025-11-054.05%
2025-11-044.36%
2025-11-034.13%
2025-10-314.10%
2025-10-304.19%
2025-10-294.19%
2025-10-284.19%
2025-10-274.20%
2025-10-244.19%
2025-10-234.18%
2025-10-224.13%
2025-10-214.06%
2025-10-204.03%
2025-10-174.09%
2025-10-164.13%
2025-10-154.11%
2025-10-144.16%
2025-10-134.18%
2025-10-104.22%
2025-10-094.14%
2025-10-084.15%
2025-10-074.14%
2025-10-064.16%
2025-10-034.11%
2025-10-024.11%
2025-10-014.10%
2025-09-304.33%
2025-09-294.46%
2025-09-264.48%
2025-09-254.51%
2025-09-244.38%
2025-09-234.26%
2025-09-224.28%
2025-09-194.28%
2025-09-184.43%
2025-09-174.45%
2025-09-164.48%
2025-09-154.46%
2025-09-124.42%
2025-09-114.33%
2025-09-104.39%
2025-09-094.37%
2025-09-084.36%
2025-09-054.31%
2025-09-044.37%
2025-09-034.31%
2025-09-024.26%
2025-08-294.25%
2025-08-284.28%
2025-08-274.25%
2025-08-264.22%
2025-08-254.24%
2025-08-224.16%
2025-08-214.14%
2025-08-204.13%
2025-08-194.14%
2025-08-184.18%
2025-08-154.13%
2025-08-144.21%
2025-08-134.23%
2025-08-124.29%
2025-08-114.29%
2025-08-084.24%
2025-08-074.30%
2025-08-064.30%
2025-08-054.07%
2025-08-043.63%
2025-08-013.69%
2025-07-313.71%
2025-07-303.64%
2025-07-293.61%
2025-07-283.64%
2025-07-253.58%
2025-07-243.55%
2025-07-233.54%
2025-07-223.59%
2025-07-213.70%
2025-07-183.72%
2025-07-173.68%
2025-07-163.67%
2025-07-153.75%
2025-07-143.69%
2025-07-113.71%
2025-07-103.65%
2025-07-093.70%
2025-07-083.69%
2025-07-073.74%
2025-07-033.68%
2025-07-023.69%
2025-07-013.77%
2025-06-303.92%
2025-06-273.95%
2025-06-263.93%
2025-06-253.91%
2025-06-243.95%
2025-06-234.02%
2025-06-203.79%
2025-06-183.78%
2025-06-173.78%
2025-06-163.71%
2025-06-133.71%
2025-06-123.69%
2025-06-113.76%
2025-06-103.74%
2025-06-093.78%
2025-06-063.78%
2025-06-053.82%
2025-06-043.82%
2025-06-033.79%
2025-06-023.80%
2025-05-303.80%
2025-05-293.87%

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Thousand Oaks, CA
28,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Bradway